People with a variant copy of the TREM2 gene have an increased risk of developing Alzheimer's disease, but researchers are only beginning to understand why.
A Genentech study has uncovered details of how a type of immune cell helps the brain get rid of the tiny amyloid-beta aggregates that can clump together to form the plaques characteristic of Alzheimer's. The researchers, reporting July 20 in Neuron, found that TREM2 mutations can derail the immune cell's plaque-clearing activity, as can two other genes already known to increase a person's risk for Alzheimer's: APOE and APOJ (known as clusterin).
"I think we're only scratching the surface of what TREM2 does," said Morgan Sheng, a senior author of the paper and Vice-President of Neuroscience at Genentech.